Overview

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

Status:
Withdrawn

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophylactic benefits of HCQ has not been clearly defined yet.

Phase:

N/A

Details

Lead Sponsor:

Texas Cardiac Arrhythmia Research Foundation

Treatments:

Hydroxychloroquine